Korsana Biosciences, Inc. (KRSA)
31.05
+0.62
(+2.04%)
USD |
NASDAQ |
Nov 06, 16:00
31.42
+0.37
(+1.19%)
After-Hours: 20:00
Korsana Biosciences Research and Development Expense (Quarterly) : 42.14M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 42.14M |
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.73M |
| December 31, 2025 | 0.519M |
| September 30, 2025 | 20.48M |
| June 30, 2025 | 0.056M |
| March 31, 2025 | 0.036M |
| December 31, 2024 | 0.056M |
| September 30, 2024 | 0.081M |
| June 30, 2024 | 0.105M |
| March 31, 2024 | 0.044M |
| December 31, 2023 | 0.024M |
| September 30, 2023 | 0.58M |
| June 30, 2023 | 0.339M |
| March 31, 2023 | 0.572M |
| December 31, 2022 | 1.176M |
| September 30, 2022 | 1.414M |
| June 30, 2022 | 10.22M |
| March 31, 2022 | 9.743M |
| Date | Value |
|---|---|
| December 31, 2021 | 10.46M |
| September 30, 2021 | 7.032M |
| June 30, 2021 | 12.05M |
| March 31, 2021 | 8.092M |
| December 31, 2020 | 12.09M |
| September 30, 2020 | 13.70M |
| June 30, 2020 | 13.79M |
| March 31, 2020 | 16.82M |
| December 31, 2019 | 20.68M |
| September 30, 2019 | 22.30M |
| June 30, 2019 | 25.76M |
| March 31, 2019 | 25.92M |
| December 31, 2018 | 22.45M |
| September 30, 2018 | 21.50M |
| June 30, 2018 | 22.25M |
| March 31, 2018 | 21.51M |
| December 31, 2017 | 24.37M |
| September 30, 2017 | 20.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Q32 Bio, Inc. | 5.149M |
| IRulya Therapeutics, Inc. | 5.461M |
| Climb Bio, Inc. | 10.85M |
| PepGen Inc. | 12.22M |
| Bridgebio Oncology Therapeutics, Inc. | 49.22M |